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Abstracts / International Journal of Surgery 36 (2016) S31eS132 S53Conclusion: Breast reconstruction following mastectomy is associated
with high levels of patient satisfaction, particularly among those who have
undergone delayed reconstruction. Higher complication rates were noted
in patients who received post mastectomy radiation. Breast reconstruction
should be discussed with patients undergoing mastectomy.http://dx.doi.org/10.1016/j.ijsu.2016.08.112
0768: MANAGEMENT OF AROMATASE INHIBITOR-INDUCED BONE LOSS
IN BREAST CANCER PATIENTS
N. Husnoo 1,*, M. Shaan Goonoo 2, S. Abbas 3. 1Barnsley District General
Hospital, Barnsley, UK; 2Royal Blackburn Hospital, Blackburn, UK;
3Kensington Partnership, Bradford, UK.
Aim: Aromatase-inhibitors (AIs), used in breast cancer treatment, increase
bone loss rate. This audit evaluates adherence to the “Guidance for the
Management of Breast Cancer Treatment-Induced Bone Loss” (UK expert
group consensus, 2008) in patients on AIs at a large general practice.
Method: Data was retrospectively collected on all patients registered at
our practice currently, or previously, on an AI for breast cancer treatment.
Result: 12 of the 14 patients identiﬁed were eligible for a baseline done
density screen upon AI initiation. 25% (n ¼ 3) did not get screened and
therefore received no subsequent fracture-risk management. 9 had a
baseline screen and appropriate drug therapy. Seven required repeat two-
yearly scans but only three were scanned. Baseline screens were mainly
requested by breast specialists (n ¼ 5) or by the general practitioner at the
breast specialists' request (n ¼ 3).
Conclusion: Management of AI-induced bone loss in our patients needs
improvement. To our knowledge no study has been performed in the UK to
assess adherence to bone loss management guidance in breast cancer
patients. Larger centres should audit their practice to ascertain the
magnitude of the problem. It should be clariﬁed how the responsibility of
bone loss management can be shared between primary and secondary
care.http://dx.doi.org/10.1016/j.ijsu.2016.08.113
0838: UPTAKE OF RISK REDUCING SURGERY IN BRCA GENE MUTATION
CARRIERS IN WALES
J. Long 1,*, T. Evans 1, D. Bailey 3, M. Lewis 3, K. Gower-Thomas 2, A. Murray 1.
1University Hospital of Wales, Cardiff, UK; 2Royal Glamorgan Hospital,
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Introduction:Women who inherit a mutated copy of the BRCA gene have
a higher lifetime risk of developing breast cancer. No large epidemiological
studies exist looking at BRCA carriers in the UK.
Method: All patients in Wales with BRCA1/BRCA2 mutation between
1995e2014 were identiﬁed from a prospectively gathered database.
Retrospective analysis of genetics case-notes was performed.
Result: 412 living females, median age 43(18e81) at time of testing, were
included.
Of 202 womenwho underwent diagnostic testing (symptomatic) 178 (88%)
had breast cancer, 43 had ovarian cancer and 19 had both at time of testing.
50 women from the diagnostic group who had not already undergone
bilateral mastectomies (29%) subsequently underwent risk-reducing
mastectomies (RRM); 79 women who had breast-conserving surgery for
cancer prior to testing did not have subsequent RRM.
210 women underwent predictive testing (family history, asymptomatic).
50% of predictive tests were carried out in the last 4 years. 10 women(5%)
developed breast cancer after testing, none had previously undergone risk-
reducing surgery. 64 patients from predictive group (30%) underwent
RRM.
Conclusion: This unique study of BRCA carriers in Wales shows consid-
erable variation in uptake of risk-reducing surgery with signiﬁcant im-
plications for service allocation and screening demands for this high-risk
group.http://dx.doi.org/10.1016/j.ijsu.2016.08.114
0933: AUDIT ON USE OF ONCOTYPE DX (ODX) TO GUIDE MULTIDISCI-
PLINARY TEAM (MDT) REGARDING CHEMOTHERAPY IN EARLY BREAST
CANCER
J. Keay*, A. Abbas, J. Kokan, C. Roshanlall. East Cheshire Trust, Macclesﬁeld,
UK.
Background: ODX assay helps a breast MDT decide if patients with early
breast cancer will beneﬁt from chemotherapy. Costing around £2,500,
NICE has issued guidance for MDTs on the option to use ODX. On average
six chemotherapy sessions are needed for breast cancer (£4,000 per ses-
sion). In our department this test is only offered to early breast cancer
patients and our aim was to assess how it guided our MDT regarding
chemotherapy.
Method: All the patients who had an ODX assay were identiﬁed
(2014e2015). Patients who did not have an ODX assay but had a Not-
tingham prognostic index 3.4 were also identiﬁed (2013e2014). MDT
outcome notes were retrospectively studied to note if ODX aided the MDT
decision regarding chemotherapy.
Result: 39 patients had ODX assay performed and most had Grade 3 tu-
mours (48.7%). It informed decision in all patients except one (2.5%). In 23
patients (59%) recurrence score was low (<18) and guided MDT that
chemotherapy will not provide any treatment beneﬁt. 31 patients (79%)
had radiotherapy and all had hormone therapy.
Conclusion: ODX test prevented chemotherapy in more than half of our
early breast cancer patients. In addition it's economical to use, saving the
NHS about £20,000 per patient.http://dx.doi.org/10.1016/j.ijsu.2016.08.115
0994: INTRODUCTION OF THE NEW GUIDELINES ON THE MANAGEMENT
OF THE AXILLA AT WARWICK BREAST UNIT, FOR WOMEN WITH
BREAST CANCER
L. Henderson*, H. Tafazal, S. Harries, L. Jones, D. Clarke. Warwick Hospital,
Warwick, UK.
Introduction: The Association of Breast Surgeons(ABS) recently published
guidelines on the management of the axilla. They state that in post-
menopausal patients with 2 sentinel nodes(SN) positive for macro-
metastasis, no further axillary treatment is required in those with disease
deemed low-risk of recurrence (T1, grade 1-2, ER positive/HER2 negative
and receiving whole breast radiotherapy).
Aim: determine if women with low-burden axillary disease would be
adversely affected by the implementation of the ABS guidelines.
Method: ABS guidelines were retrospectively applied to patients under-
going SN biopsy 2014e2015 at Warwick Hospital. Clinical data (demo-
graphics,tumour and lymph-node histology) was collated from electronic
records.
Result: Study group¼ 454 patients. 270 patients were postmenopausal. Of
these, 67(25%) patients were found to have macrometastasis in 1-2 SN. 17
of these 67 patients would have had no further axillary treatment based on
ABS guidelines. Of this group 13(76%) had no further disease on ANC, while
4(24%) were found to have disease in 3 lymph-nodes.
Conclusion: Following ABS recommendations, 76% of patients meeting
criteria for low-risk disease, had no further axillary disease. 24% were
found to have signiﬁcant axillary macrometastasis. We conclude that
almost a quarter of our patients may have been adversely affected by the
implementation of the ABS guidelines.http://dx.doi.org/10.1016/j.ijsu.2016.08.116
1043: ASSESSMENT OF THE EFFICACY OF AXILLARY USS AND CYTOLOGY
IN PREDICTING THE AXILLARY NODAL BURDEN IN PRIMARY BREAST
CANCER
L. Balance*, P. Asad, M. Bramley. North Manchester, North West, UK.
